Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 225

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Diagnostic methods and treatment options for focal cortical dysplasia

Open access
Guerrini, Renzo, Duchowny, Michael, Jayakar, Prasanna, Krsek, Pavel, Kahane, Philippe, Tassi, Laura, Melani, Federico, Polster, Tilman, Andre, Véronique M., Cepeda, Carlos, Krueger, Darcy A., Cross, J. Helen, Spreafico, Roberto, Cosottini, Mirco, Gotman, Jean, Chassoux, Francine, Ryvlin, Philippe, Bartolomei, Fabrice, Bernasconi, Andrea, Stefan, Hermann, Miller, Ian, Devaux, Bertrand, Najm, Imad, Giordano, Flavio, Vonck, Kristl, Barba, Carmen, Blumcke, Ingmar · 2015 · Epilepsia

Abstract

Summary: Our inability to adequately treat many patients with refractory epilepsy caused by focal cortical dysplasia (FCD), surgical inaccessibility and failures are significant clinical drawbacks. The targeting of physiologic features of epileptogenesis in FCD and colocalizing functionality has enhanced completeness of surgical resection, the main determinant of outcome. Electroencephalography (EEG)–functional magnetic resonance imaging (fMRI) and magnetoencephalography are helpful in guiding electrode implantation and surgical treatment, and high‐frequency oscillations help defining the extent of the epileptogenic dysplasia. Ultra high‐field MRI has a role in understanding the laminar organization of the cortex, and fluorodeoxyglucose–positron emission tomography (FDG‐PET) is highly sensitive for detecting FCD in MRI‐negative cases. Multimodal imaging is clinically valuable, either by improving the rate of postoperative seizure freedom or by reducing postoperative deficits. However, there is no level 1 evidence that it improves outcomes. Proof for a specific effect of antiepileptic drugs (AEDs) in FCD is lacking. Pathogenic mutations recently described in mammalian target of rapamycin (mTOR) genes in FCD have yielded important insights into novel treatment options with mTOR inhibitors, which might represent an example of personalized treatment of epilepsy based on the known mechanisms of disease. The ketogenic diet (KD) has been demonstrated to be particularly effective in children with epilepsy caused by structural abnormalities, especially FCD. It attenuates epigenetic chromatin modifications, a master regulator for gene expression and functional adaptation of the cell, thereby modifying disease progression. This could imply lasting benefit of dietary manipulation. Neurostimulation techniques have produced variable clinical outcomes in FCD. In widespread dysplasias, vagus nerve stimulation (VNS) has achieved responder rates >50%; however, the efficacy of noninvasive cranial nerve stimulation modalities such as transcutaneous VNS (tVNS) and noninvasive (nVNS) requires further study. Although review of current strategies underscores the serious shortcomings of treatment‐resistant cases, initial evidence from novel approaches suggests that future success is possible.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.13200

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Guerrini, R., Duchowny, M., Jayakar, P., Krsek, P., Kahane, P., Tassi, L., Melani, F., Polster, T., Andre, V. M., Cepeda, C., Krueger, D. A., Cross, J. H., Spreafico, R., Cosottini, M., Gotman, J., Chassoux, F., Ryvlin, P., Bartolomei, F., Bernasconi, A., Stefan, H., Miller, I., Devaux, B., Najm, I., Giordano, F., Vonck, K., Barba, C., & Blumcke, I.
Venue
Epilepsia
Publisher
Wiley
Published
2015-10-05
Volume
56
Issue
11
Pages
1669-1686
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W1929006084
Cited by
225
References
6
FWCI
16.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.